Adebrelimab
Cross-source consensus on Adebrelimab from 1 sources and 3 claims.
1 sources · 3 claims
How it works
Comparisons
Evidence quality
Highlighted claims
- Adebrelimab acts by blocking PD-L1 to reactivate T-cell antitumor responses. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
- The TOPAZ-1 and KEYNOTE-966 trials established that PD-1/PD-L1 inhibitors combined with chemotherapy produce objective response rates of 25–30% in advanced biliary tract carcinoma. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
- Adding VEGF tyrosine kinase inhibitors to PD-1/PD-L1 inhibitors and chemotherapy increases objective response rates to 35–80% in phase II studies. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial